Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated…
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health…
Ann Arbor, MI, March 13, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational and educational purposes only and…
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around…
BHUBANESWAR, India, March 2, 2026 /PRNewswire/ -- Manipal Hospital Bhubaneswar hosted a press meet on 24th February, 2026 reinforcing its reputation…
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and…
March 01, 2026 09:45 ET | Source: Celldex Therapeutics, Inc. - Late breaking Poster Presentation at AAAAI -- Ability to…
February 23, 2026 17:10 ET | Source: Kyntra Bio FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen…
ZUG, Switzerland, Feb. 12, 2026 /PRNewswire/ -- Berlin Heals Holding AG, a MedTech company focused on transformative therapies for heart failure,…
Breakthrough Phase 2 Trial Results Show Promise for Patients Ineligible for Standard Reperfusion TherapiesData Presented at International Stroke ConferenceData Show…